This inventor holds 150 USPTO granted patents and 26 published patent applications, plus 7 CIPO patents and 40 EPO patents, primarily in Pharmaceutical Chemistry (CPC class A61K45-06). Top assignees: Bayer Aktiengesellschaft, Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft. Active years: 1989-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Wuppertal, DE (1989 - 1997)
- Soligen, DE (2004)
- D 51368 Leverkusen, DE (2009)
- Munich, DE (2016)
- München, DE (2017)
- Grottaferrata, IT (2017 - 2021)
- Solingen, DE (1995 - 2024)
Company Filing History:
68 out of 12,266 
31 out of 721 
31 out of 386 
Years Active: 1989-2024
Areas of Expertise:
Title: Johannes-Peter Stasch: A Trailblazer in Pharmaceutical Innovations
Introduction:
Johannes-Peter Stasch, a resident of Solingen, Germany, is a prolific inventor and a prominent name in the field of pharmaceutical innovations. With an impressive portfolio of 149 patents, Stasch has contributed extensively to the development of novel treatment options for various diseases, particularly cardiovascular disorders. In this article, we will delve into his latest patents, career highlights, collaborations, and celebrate his remarkable contributions to the world of medical advancements.
Latest Patents:
Stasch's recent patents showcase his expertise in developing groundbreaking pharmaceutical compounds and their applications. Two noteworthy examples include:
1. Substituted 5-fluoro-1H-pyrazolopyridines and their use:
This patent application introduces a new class of substituted 5-fluoro-1H-pyrazolopyridines, which have demonstrated potential for treating and preventing various diseases. These compounds hold promise for cardiovascular disorder treatments, offering novel therapeutic options to patients.
2. Branched 3-phenylpropionic acid derivatives and their use:
Stasch's inventive work in this patent involves branched or cyclic alkyl substituents in 3-phenylpropionic acid derivatives. These compounds have shown potential for effectively treating cardiovascular diseases. Their unique properties make them key candidates for the development of future medicinal treatments.
Career Highlights:
Throughout his career, Stasch has made significant contributions to the pharmaceutical industry. He has carried out groundbreaking research and development activities in collaboration with renowned organizations, including:
1. Bayer Corporation:
Stasch has been associated with Bayer Aktiengesellschaft, a multinational pharmaceutical and life sciences company. His tenure at Bayer Corporation allowed him to leverage the resources and expertise of a leading industry player, driving innovation in drug development and patents.
2. Collaboration with Frank Wunder and Andreas Knorr:
Stasch has had the privilege of collaborating with esteemed individuals such as Frank Wunder and Andreas Knorr. These collaborations have resulted in fruitful partnerships, leading to the creation of influential patents and advancements in cardiovascular treatments.
Conclusion:
Johannes-Peter Stasch's dedication to innovation and patenting has helped shape the landscape of pharmaceutical advancements, particularly in the field of cardiovascular disorders. His extensive portfolio of patents, including the development of novel chemical compounds and their applications, highlights his remarkable contributions to medical science. Stasch's collaborations with leading industry players have further cemented his position as a trailblazer in the field of pharmaceutical innovations. As we celebrate his achievements, we eagerly anticipate the impact his future endeavors will have on the world of healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile